This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Benoit, P. Articles by Duverger, N. Search for Related Content PubMed PubMed Citation Articles by Benoit, P. Articles by Duverger, N. Pubmed/NCBI databases Substance via MeSH Related Collections Pathophysiology Genetically altered mice Lipid and lipoprotein metabolism

(Circulation. 1999;99:105-110.)
© 1999 American Heart Association, Inc.

Basic Science Reports

Somatic Gene Transfer of Human ApoA-I Inhibits Atherosclerosis Progression in Mouse Models

Patrick Benoit, PhD; Florence Emmanuel, PhD; Jean Michel Caillaud, MD; Laurent Bassinet; Graciela Castro, PhD; Pierre Gallix, DVM; Jean Charles Fruchart, PhD; Didier Branellec, PhD; Patrice Denèfle, PhD; Nicolas Duverger, PhD

From Rhône-Poulenc Rorer–Gencell Division, Cardiovascular Department, Centre de recherche de Vitry-Alfortville, Vitry sur Seine, and Institut Pasteur (G.C., J.C.F.), Lille, France.

Correspondence to Nicolas Duverger, Rhône-Poulenc Rorer–Gencell Division, Cardiovascular Department, Centre de recherche de Vitry-Alfortville, 13, Quai Jules Guesde-BP 14, 94403 Vitry sur Seine Cedex, France. E-mail nicolas.duverger{at}rp-rorer.fr

Background—Apolipoprotein (apo) A-I is the major component of HDL, and it displays antiatherogenic properties.

Methods and Results—The human apoA-I gene has been transferred into different mouse models by use of a recombinant adenovirus under the control of an RSV-LTR promoter (AV RSV apoA-I). Administration of AV RSV apoA-I to C57BL/6 mice resulted in moderate expression of human apoA-I for 3 weeks, leading to a transient elevation (40% at day 11 after injection) of HDL cholesterol concentration. In contrast, administration of AV RSV apoA-I to human apoA-I–transgenic mice induced a large increase of human apoA-I and HDL cholesterol concentrations (300% and 360%, respectively, at day 14 after injection) for 10 weeks, indicating that an immune response to the transgene was one major hurdle for long-term duration of expression. Recombinant adenovirus expressing human apolipoprotein A-I (AV RSV apoA-I) was also injected into human apoA-I–transgenic/apoE-deficient mice, which are prone to develop atherosclerosis. Over a 6-week period, overexpression of human apoA-I inhibited fatty streak lesion formation by 56% in comparison with control.

Conclusions—Somatic gene transfer of human apoA-I prevents the development of atherosclerosis in the mouse model.

Key Words: genes • apolipoproteins • atherosclerosis

This article has been cited by other articles:

				A. M. Scanu and C. Edelstein HDL: bridging past and present with a look at the future FASEB J, December 1, 2008; 22(12): 4044 - 4054. [Abstract] [Full Text] [PDF]

				L. T. Bloedon, R. Dunbar, D. Duffy, P. Pinell-Salles, R. Norris, B. J. DeGroot, R. Movva, M. Navab, A. M. Fogelman, and D. J. Rader Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients J. Lipid Res., June 1, 2008; 49(6): 1344 - 1352. [Abstract] [Full Text] [PDF]

				M. Hashimoto, T. Kadowaki, T. Tsukuba, and K. Yamamoto Selective Proteolysis of Apolipoprotein B-100 by Arg-Gingipain Mediates Atherosclerosis Progression Accelerated by Bacterial Exposure J. Biochem., November 1, 2006; 140(5): 713 - 723. [Abstract] [Full Text] [PDF]

				M. D. Ashen and R. S. Blumenthal Low HDL Cholesterol Levels N. Engl. J. Med., September 22, 2005; 353(12): 1252 - 1260. [Full Text] [PDF]

				M. L. Gruen, M. R. Plummer, W. Zhang, K. A. Posey, M. Linton, S. Fazio, and A. H. Hasty Persistence of high density lipoprotein particles in obese mice lacking apolipoprotein A-I J. Lipid Res., September 1, 2005; 46(9): 2007 - 2014. [Abstract] [Full Text] [PDF]

				R. Out, M. Hoekstra, J. A. A. Spijkers, J. K. Kruijt, M. van Eck, I. S. T. Bos, J. Twisk, and T. J. C. Van Berkel Scavenger receptor class B type I is solely responsible for the selective uptake of cholesteryl esters from HDL by the liver and the adrenals in mice J. Lipid Res., November 1, 2004; 45(11): 2088 - 2095. [Abstract] [Full Text] [PDF]

				C. M. Ballantyne and V. Nambi Apolipoprotein A-I and high-density lipoprotein: Is this the beginning of the era of noninvasive angioplasty? J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1436 - 1438. [Full Text] [PDF]

				X. Li, K.-Y. Chyu, J. R. F. Neto, J. Yano, N. Nathwani, C. Ferreira, P. C. Dimayuga, B. Cercek, S. Kaul, and P. K. Shah Differential Effects of Apolipoprotein A-I-Mimetic Peptide on Evolving and Established Atherosclerosis in Apolipoprotein E-Null Mice Circulation, September 21, 2004; 110(12): 1701 - 1705. [Abstract] [Full Text] [PDF]

				S. Wen, S. Graf, P. G. Massey, and D. A. Dichek Improved Vascular Gene Transfer With a Helper-Dependent Adenoviral Vector Circulation, September 14, 2004; 110(11): 1484 - 1491. [Abstract] [Full Text] [PDF]

				K. S. Meir and E. Leitersdorf Atherosclerosis in the Apolipoprotein E-Deficient Mouse: A Decade of Progress Arterioscler Thromb Vasc Biol, June 1, 2004; 24(6): 1006 - 1014. [Abstract] [Full Text] [PDF]

				M. Zabalawi, S. Bhat, T. Loughlin, M. J. Thomas, E. Alexander, M. Cline, B. Bullock, M. Willingham, and M. G. Sorci-Thomas Induction of Fatal Inflammation in LDL Receptor and ApoA-I Double-Knockout Mice Fed Dietary Fat and Cholesterol Am. J. Pathol., September 1, 2003; 163(3): 1201 - 1213. [Abstract] [Full Text] [PDF]

				L. M. Belalcazar, A. Merched, B. Carr, K. Oka, K.-H. Chen, L. Pastore, A. Beaudet, and L. Chan Long-Term Stable Expression of Human Apolipoprotein A-I Mediated by Helper-Dependent Adenovirus Gene Transfer Inhibits Atherosclerosis Progression and Remodels Atherosclerotic Plaques in a Mouse Model of Familial Hypercholesterolemia Circulation, June 3, 2003; 107(21): 2726 - 2732. [Abstract] [Full Text] [PDF]

				B. G. Brown, M. C. Cheung, A. C. Lee, X.-Q. Zhao, and A. Chait Antioxidant Vitamins and Lipid Therapy: End of a Long Romance? Arterioscler Thromb Vasc Biol, October 1, 2002; 22(10): 1535 - 1546. [Abstract] [Full Text] [PDF]

				J. X. Rong, J. Li, E. D. Reis, R. P. Choudhury, H. M. Dansky, V. I. Elmalem, J. T. Fallon, J. L. Breslow, and E. A. Fisher Elevating High-Density Lipoprotein Cholesterol in Apolipoprotein E-Deficient Mice Remodels Advanced Atherosclerotic Lesions by Decreasing Macrophage and Increasing Smooth Muscle Cell Content Circulation, November 13, 2001; 104(20): 2447 - 2452. [Abstract] [Full Text] [PDF]

				P. K. Shah, S. Kaul, J. Nilsson, and B. Cercek Exploiting the Vascular Protective Effects of High-Density Lipoprotein and its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part II Circulation, November 13, 2001; 104(20): 2498 - 2502. [Full Text] [PDF]

				P. K. Shah, S. Kaul, J. Nilsson, and B. Cercek Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part I Circulation, November 6, 2001; 104(19): 2376 - 2383. [Full Text] [PDF]

				J. D. Smith An A+ for Macrophages in Reducing Atherosclerosis? Arterioscler Thromb Vasc Biol, November 1, 2001; 21(11): 1710 - 1711. [Full Text] [PDF]

				A. S. Major, D. E. Dove, H. Ishiguro, Y. R. Su, A. M. Brown, L. Liu, K. J. Carter, M. F. Linton, and S. Fazio Increased Cholesterol Efflux in Apolipoprotein AI (ApoAI)-Producing Macrophages as a Mechanism for Reduced Atherosclerosis in ApoAI(-/-) Mice Arterioscler Thromb Vasc Biol, November 1, 2001; 21(11): 1790 - 1795. [Abstract] [Full Text] [PDF]

				R. Khurana, J. F. Martin, and I. Zachary Gene Therapy for Cardiovascular Disease: A Case for Cautious Optimism Hypertension, November 1, 2001; 38(5): 1210 - 1216. [Abstract] [Full Text] [PDF]

				A. von Eckardstein, J.-R. Nofer, and G. Assmann High Density Lipoproteins and Arteriosclerosis : Role of Cholesterol Efflux and Reverse Cholesterol Transport Arterioscler Thromb Vasc Biol, January 1, 2001; 21(1): 13 - 27. [Abstract] [Full Text] [PDF]

				G. THEILMEIER, B. DE GEEST, P. P. VAN VELDHOVEN, D. STENGEL, C. MICHIELS, M. LOX, M. LANDELOOS, M. J. CHAPMAN, E. NINIO, D. COLLEN, et al. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice FASEB J, October 1, 2000; 14(13): 2032 - 2039. [Abstract] [Full Text]

				M. O Hiltunen, M. P Turunen, M. Laitinen, and S. Yla-Herttuala Insights into the molecular pathogenesis of atherosclerosis and therapeutic strategies using gene transfer Vascular Medicine, February 1, 2000; 5(1): 41 - 48. [Abstract] [PDF]

				P. Sinnaeve, O. Varenne, D. Collen, and S. Janssens Gene therapy in the cardiovascular system: an update Cardiovasc Res, December 1, 1999; 44(3): 498 - 506. [Abstract] [Full Text] [PDF]

				H. M. Dansky and E. A. Fisher High-Density Lipoprotein and Plaque Regression : The Good Cholesterol Gets Even Better Circulation, October 26, 1999; 100(17): 1762 - 1763. [Full Text] [PDF]

				R. K. Tangirala, K. Tsukamoto, S. H. Chun, D. Usher, E. Pure, and D. J. Rader Regression of Atherosclerosis Induced by Liver-Directed Gene Transfer of Apolipoprotein A-I in Mice Circulation, October 26, 1999; 100(17): 1816 - 1822. [Abstract] [Full Text] [PDF]

				T. Arai, F. Rinninger, L. Varban, V. Fairchild-Huntress, C.-P. Liang, W. Chen, T. Seo, R. Deckelbaum, D. Huszar, and A. R. Tall Decreased selective uptake of high density lipoprotein cholesteryl esters in apolipoprotein E knock-out mice PNAS, October 12, 1999; 96(21): 12050 - 12055. [Abstract] [Full Text] [PDF]

				B. J. M. van Vlijmen and J. Herz Gene Targets and Approaches for Raising HDL Circulation, January 12, 1999; 99(1): 12 - 14. [Full Text] [PDF]

				H. Ishiguro, H. Yoshida, A. S. Major, T. Zhu, V. R. Babaev, M. F. Linton, and S. Fazio Retrovirus-mediated Expression of Apolipoprotein A-I in the Macrophage Protects against Atherosclerosis in Vivo J. Biol. Chem., September 21, 2001; 276(39): 36742 - 36748. [Abstract] [Full Text] [PDF]